Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Sep 12, 2026
Can you apply?
This grant is for researchers and research institutions conducting NIH-supported clinical trials investigating rapid-acting psychotropic interventional drugs (RAPIDs). The program focuses on methodological challenges specific to this therapeutic area. Eligible applicants include academic health centers, research hospitals, independent research institutions, and NIH-designated cancer centers with relevant clinical trial infrastructure. The grant supports U.S. domestic research and requires a significant clinical trial component as a mandatory element. Activities include developing improved trial methodologies, addressing patient recruitment and retention challenges, designing appropriate control groups, managing endpoint selection for rapid-response therapeutics, and other scientific approaches to strengthen RAPID drug trial design and execution.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (R&R) application form
- Project Narrative (specific aims, significance, innovation, approach, timeline)
- Budget and budget justification
- Biographical sketches (key personnel, in NIH format)
- Facilities and Resources
- Letters of support and institutional commitment
- IRB approval letter or evidence of pending IRB review
- Detailed clinical trial protocol or protocol summary
- Safety monitoring plan
- Data management and statistical analysis plan
- Letters of institutional support confirming research infrastructure and trial readiness
Program contact
- 👤 National Institutes of Health
- 📧 DTRcommunications@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.242 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$92,363,814
-
$91,890,365
-
$67,491,373
-
$64,705,159
-
$63,991,707
-
$48,653,752
-
$40,395,082
-
$38,475,557
-
$36,135,833
-
$35,940,675
Top States by Funding
- CA 15 awards $433.4M
- MA 10 awards $257.3M
- WA 4 awards $191.8M
- NY 6 awards $185.7M
- PA 6 awards $111.3M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.242). How funding has trended year over year.
| 2024 | $1,722,300,004 | |
| 2025 | $1,726,864,191 | |
| 2026 est. | $99,221,272 |
FAQ
Who is eligible to apply for this R01 RAPID clinical trial grant?
Academic institutions, research hospitals, and nonprofits with active clinical trial experience and appropriate regulatory infrastructure can apply. If you lead or co-lead a federally funded R01 project, you generally meet experience requirements.
Is a clinical trial mandatory for this grant?
Yes, a clinical trial is required. Your proposed project must involve active clinical testing of rapid-acting psychotropic interventional drugs with human subjects.
What types of methodological challenges does this grant prioritize?
Focus areas typically include trial design optimization for drugs with rapid onset, patient recruitment/retention strategies, endpoint selection, control group design, data monitoring procedures, and statistical approaches suited to rapid-response therapeutics.
What is the typical funding range and project period?
R01 grants typically fund $150,000–$500,000+ in direct costs, depending on scope and institutional burden rates. Project periods usually range from 3–5 years.
When are deadlines, and how competitive is this program?
The next deadline is October 11, 2026. R01 clinical trial grants are highly competitive. Demonstrating methodological innovation, strong preliminary data, and experienced clinical trial infrastructure significantly improves competitiveness.
💡 Tips for applicants
- Start with a strong preliminary study or pilot data showing feasibility of your proposed methodological approach and the RAPID drug being studied; reviewers expect proof of concept before committing R01 funding.
- Clearly articulate the specific methodological gap you are addressing (e.g., endpoint measurement, recruitment challenges, control design) rather than simply describing a general clinical trial.
- Assemble a multidisciplinary team including biostatisticians, clinical pharmacologists, trial design experts, and experienced clinical research coordinators to demonstrate capacity.
- Build detailed safety monitoring and data management plans early; reviewers pay close attention to human subjects protections and regulatory compliance in psychotropic drug trials.
- Engage your institution's research administration and regulatory affairs offices from the start to confirm clinical trial infrastructure, IRB support, and budget capability.
⚠️ Common mistakes
Applications often fail because they treat the clinical trial as secondary to the methodological question, rather than tightly integrating trial design innovation into the science narrative. Another frequent weakness is insufficient preliminary data or unclear evidence that the proposed methodology addresses a real gap in current RAPID trial science. Finally, many applicants underestimate the complexity of regulatory pathways and safety oversight required for psychotropic interventional drugs, leading to unrealistic timelines or inadequate safety plans.
Similar grants
- OPEN Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 – Clinical Trial Required) — National Institutes of Health
- OPEN Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) — National Institutes of Health
- OPEN Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 Clinical Trial Required) — National Institutes of Health
- OPEN Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required) — National Institutes of Health